Thoratec Q1 revenue drops 7%; Capital Royalty fund targets healthcare/med tech;

 @FierceMedDev: Implant successfully predicts human epilepsy seizures. Item | Follow @FierceMedDev

 @MarkHFierce: A Dx to predict prostate cancer recurrence produced some hopeful early results. DxExtra | Follow @MarkHFierce

 @DamianFierce: Life Tech posts tepid quarterly results as Thermo waits with $13.6B. News | Follow @DamianFierce

> Thoratec ($THOR), a maker of heart pumps and other circulatory support devices, faced a 7% decline in revenue during its fiscal 2013 first quarter, something the company said it expected. Release

> Sen. Lamar Alexander, a Tennessee Republican, is reiterating his support for a repeal of the 2.3% medical device industry tax, though he admits Congress hasn't yet figured out how to replace the money it would generate. Story

> The U.K.'s Probe Scientific will license its blood sampling microdialysis tech to Italy's A. Menarini Diagnostics to help that company enhance an intravenous glucose-monitoring product. Release

> TearScience's LipiFlow devices to treat dry eye were featured on the syndicated talk show "The Doctors." Release

> Scientists have come up with a tiny digital camera with 200 lenses that mimic the multiple eyes of ants. The idea is that it could help build a better endoscope tool. Story

> Capital Royalty has launched a new $805 million fund focused on royalty financing, an increasing alternative for med tech companies that are close to a commercial launch and seeking funding. Story

> Volcano ($VOLC) experienced moderate revenue growth during its 2013 first quarter but lost $3.2 million, based in part on a number of one-time expenses for the maker of coronary and peripheral vascular disease surgical tools. Release

Biotech News

 @FierceBiotech: Industry Voices: Who will figure out how to make a business out of fecal transplants? Feature | Follow @FierceBiotech

 @JohnCFierce: Bristol-Myers' "smart bomb" deal pushes Ambrx 12-month deal tally to $715M. More | Follow @JohnCFierce

 @RyanMFierce: Sanofi lets go of rights to Regeneron's antibodies in ophthalmology in $65M agreement. Article | Follow @RyanMFierce

> AltheRx Pharma adds $15M, new CEO and ex-AstraZeneca exec. Article

> Biotech financier Blech gets jail time in 'No mercy' sentence. Report

> Arena shares sink after biotech withdraws marketing app for obesity drug in Europe. News

Pharma News

 @FiercePharma: Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts. More | Follow @FiercePharma

 @EricPFierce: GSK secretly monitored chat boards for parent discussions on vaccinations. Report | Follow @EricPFierce

> Slow Medicare spending protects pharma from payment board intravention. News

> Gilead profits surge 63%, but not where Wall Street expected. Article

> Arena pulls app for weight-loss drug Belviq in EU. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.